P
ercutaneous core needle biopsy is an important tool in the evaluation of musculoskeletal lesions. Its accuracy, safety, and cost-effectiveness have been well documented. However, open or excisional biopsy remains the reference standard.
For a biopsy to be successful, it must first be considered diagnostic. This requires imparting a specific diagnosis from which the treating clinician can make a decision of whether to dismiss, monitor, or treat a lesion. Ideally, the result would also be definitive, without the possibility of additional differential diagnoses. Also, the referring clinician must have sufficient confidence in the result. If a biopsy fails to meet one or more of these criteria, it is generally considered nondiagnostic. The reported diagnostic yield of percutaneous biopsy of musculoskeletal lesions in the literature is 69-88% [1] [2] [3] [4] [5] [6] . lesions [4, 9, 11] , and in biopsies with few number of specimens [6] .
The purpose of this study was to better elucidate factors that may contribute to the success of CT-guided core needle biopsy.
Materials and Methods
This study included 493 CT-guided percutaneous core needle biopsies of soft-tissue or bone lesions, performed on 474 patients (252 male and 222 female), with a mean age of 50 years (range, 1-94 years). The procedures were performed consecutively from January 2005 to August 2008 at a single tertiary care institution.
After approval by the institutional review board, data were retrospectively acquired by one of the authors for each biopsy from the computerized hospital information system and radiology information system. The data included patient demographics, biopsy technical factors, imaging features, lesion histologic features, and clinical follow-up. CT biopsy results were compared with subsequent surgical pathologic results. For 190 lesions that did not undergo surgical biopsy or excision, CT biopsy results were compared with the final clinical diagnoses. Forty-nine equivocal biopsies with clinical followup of less than 6 months were excluded, leaving a total of 444 biopsies for statistical analysis. Clinical follow-up in the remaining cases without subsequent surgical biopsy or excision ranged from 6 to 40 months.
One of two musculoskeletal radiologists performed each needle biopsy after obtaining informed consent from the patient or a guardian. Local anesthesia was administered in all cases, and conscious sedation was used in 64 cases. For soft-tissue lesions or bone lesions with accessible soft-tissue components, three to eight core biopsy specimens were routinely obtained with an automated 14-gauge cutting needle inserted coaxially through an 11-or 12-gauge trocar (Quick-Core Biopsy Needle Set, Cook Medical). For bone lesions in which the cortex was intact, a bone-cutting biopsy device was used (KyphX, Kyphon; Jamshidi, CareFusion; or Bonopty, AprioMed). Specimens were sent in buffered formalin and saline solution for histologic analysis and possible flow cytometry or cytogenetic analysis and karyotyping. Pathologic specimens were examined by one of two experienced musculoskeletal pathologists.
On the basis of pathologic and clinical followup data, biopsies were classified as diagnostic or nondiagnostic and as accurate or inaccurate. A biopsy was considered diagnostic if a definitive pathologic diagnosis could be determined or if the result proved clinically useful and no subsequent confirmatory tissue sampling was required. A biopsy was classified as accurate if the result was consistent with subsequent surgical pathologic findings or the final clinical diagnosis in the detection of malignancy, tumor grade, and salient histologic features. Biopsies were considered successful if they were both diagnostic and accurate.
The overall biopsy success rate was calculated as the number of biopsies that were both diagnostic and accurate, divided by the total number of biopsies. Diagnostic yield and accuracy were calculated as the number of diagnostic or accurate biopsies, respectively, divided by the total number of biopsies.
Biopsy success rate, diagnostic yield, and accuracy were analyzed by subgroups using the chisquare and Fisher exact tests, when appropriate. Tested variables included lesion anatomic location (peripheral or central), use of sedation, biopsy equipment type (soft tissue or bone), bone 
Results
Of 444 biopsies, 316 (71%) were diagnostic, 382 (86%) were accurate, and 313 (70%) were considered successful (both diagnostic and accurate).
There were no statistically significant differences in biopsy success rates when evaluated by lesion anatomic location, use of sedation, biopsy equipment type, or bone lesion matrix (Table 1 ). There were, however, significant associations between biopsy success and lesion histopathologic features (Table 2) . Biopsies of lesions arising from bone were 78% successful, compared with 64% of soft-tissue lesions (p = 0.001) (Fig. 1) . Malignant and intermediate-to-high-grade neoplasms were also associated with higher biopsy success rates than benign (p < 0.0001) and low-grade (p < 0.0001) neoplasms (Table 2 and Fig. 2 ).
These same groups had significant differences in diagnostic yield; 78% of bone lesion biopsies were diagnostic, compared with 64% of soft-tissue lesions (p = 0.002). Biopsies of malignant neoplasms were more often diagnostic (80%) than those of benign neoplasms (47%; p < 0.0001). Finally, 80% of intermediate-to-high-grade neoplasms had diagnostic biopsy results, compared with 52% of low-grade neoplasms (p < 0.0001).
No significant associations were found between accuracy and biopsy technical factors, lesion imaging features, or lesion histologic type (Table 1) .
Of the 128 nondiagnostic biopsies, 68 (53%) were accurate with respect to subsequent surgical pathologic results. The majority of these were benign soft-tissue lesions (Table 3) .
Sixty-two of 444 biopsies (14%) were inaccurate. These included 32 false-negative biopsies, one false-positive biopsy, seven that were inaccurate with respect to grade, and 22 that were inaccurate with respect to lesion histopathologic features. Three of the inaccurate biopsies were considered diagnostic at the time of interpretation. One was an anaplastic ependymoma, which was initially reported as ependymoma on CT biopsy. The second was an intermediate-grade myxofibrosarcoma, previously called low-grade on CT biopsy. The third was a malignant giant cell tumor, originally reported as a (benign) giant cell tumor.
discussion
Reported rates of biopsy diagnostic yield and accuracy in the literature range from 69% to 96% [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] , with diagnostic yield inferior to accuracy in most studies [1, [3] [4] [5] 12] . Our study showed similar rates, with a diagnostic yield of 71% and accuracy of 86%. Our overall success rate, defined as both diagnostic and accurate, was 70%.
There are several potential causes for unsuccessful CT biopsy. These include, but are not limited to, failure to biopsy the lesion; failure to obtain sufficient material; the inability to render a definitive diagnosis because of nonspecific histologic features, necrosis, crush artifact, and so forth; and a lack of confidence in the biopsy result, requiring additional tissue sampling. Failure to biopsy the lesion or to obtain sufficient material can be the result of technical factors, such as difficulty accessing or penetrating a lesion. This is suggested by reports of lower biopsy success rates for lesions in or around the spine [4, 9, 11] , bone lesions without soft-tissue components [1, 11] , and sclerotic bone lesions [6, 8] . Our study found no significant difference in success rates for these subgroups; however, the sample sizes were small. Wu et al. [6] reported increased biopsy success with greater number of specimens obtained and proposed three cores for bone lesions and four cores for soft-tissue lesions as the optimal numbers. Analysis of this nature could not be performed in our retrospective study, because the number of core samples obtained was not routinely reported, and pathologic reports of specimen size varied depending on the quality of the specimen (i.e., some were reported as core lengths, others as specimen button volume).
We hypothesized that the use of sedation would result in better patient cooperation and thus greater biopsy success; however, our data showed no positive associations between the use of sedation and biopsy success, diagnostic yield, or accuracy. In fact, biopsies performed with sedation showed an accuracy rate of 78%, compared with 87% accuracy of biopsies performed without sedation. This approaches statistical significance (p = 0.05) but is of doubtful clinical significance.
Our study did find lower success rates with lesions of soft-tissue origin, which may reflect the relative lack of characteristic radiologic features in soft-tissue lesions. Bone lesions, in contrast, often have specific imaging features that can be corroborated by pathology (Fig. 1) . This finding is commensurate with other reports of lower success with soft-tissue lesions [14, 15, 20] .
Our study also showed lower success rates in biopsies of benign and low-grade neoplasms. These lesions are inherently difficult to distinguish from their higher-grade counterparts by CT biopsy because the possibility of sampling error must always be considered (Fig. 2) . For example, a CT biopsy result of "lipoma" could be considered nondiagnostic because an undersampled liposarcoma cannot be excluded. If surgical pathology confirms the diagnosis of lipoma, the CT biopsy would be considered accurate but nondiagnostic. This scenario was not rare in our study because 53% of nondiagnostic biopsies subsequently proved to be accurate. Of the nondiagnostic but accurate biopsies, the majority were benign soft-tissue lesions, including many low-grade neoplasms such as lipoma, hemangioma, or myxoma (Table 3 ). Practitioners should be aware of the limitations of CT biopsy in diagnosing these types of lesions.
Interventionalists should also take measures to increase confidence in biopsy results. Some strategies could include targeting the most aggressive-appearing portion of a lesion, avoiding necrotic areas, and sampling from multiple areas when a lesion is large.
This study was limited by its retrospective nature. There were also relatively small sample sizes of bone lesions without soft-tissue components, sclerotic bone lesions, and spine lesions, limiting evaluation of technical and imaging factors as determinants of success.
In conclusion, CT-guided core needle biopsy is generally an accurate and effective tool in the diagnosis of musculoskeletal lesions. There may be some inherent limitations in its evaluation of benign and low-grade soft-tissue neoplasms. Nonspecific imaging features and concern for sampling error likely contribute to lower diagnostic yield in CT biopsies of these lesions. 
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